

## NeuroFactor™ Increases Plasma Levels of BDNF in Humans



# NEUROFACTOR

**New Pilot Clinical Study Indicates NeuroFactor™ Whole Coffee Fruit Concentrate Increases Plasma Levels of Vital Protein Essential for Cognitive Health.**

NeuroFactor Whole Coffee Fruit Concentrate is a patented product from the whole fruit of the coffee plant, *Coffea arabica*, that recent clinical research shows has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, or even caffeine.

In a double-blind, placebo-controlled pilot human clinical study, NeuroFactor was tested against other leading botanicals, including Green Coffee Bean Extract, Natural Coffee Caffeine, and Grape Seed Extract for effect on Brain-Derived Neurotrophic Factor (BDNF). **Only NeuroFactor showed a statistically significant ability to increase BDNF in humans.**

### Brain-Derived Neurotrophic Factor (BDNF)

Brain-Derived Neurotrophic Factor (BDNF) is a protein active in the brain and central and peripheral nervous systems with a critical role in neuron development, maintenance, and repair and in protecting against neuro-degeneration. BDNF is important for a variety of processes, including learning, memory, alertness, mood, controlling body weight, and controlling energy metabolism.<sup>i,ii,iii,iv,v,vi</sup>

Low levels of BDNF have been associated with numerous

deleterious conditions, including obesity, diabetes, metabolic syndrome, depression, cardiovascular diseases, cognitive impairment, and Alzheimer's disease.<sup>vii,viii,ix,x,xi,xii,xiii,xiv,xv</sup>


**Clinical Study Results:** Double-blind, placebo-controlled, pilot human clinical study to assess the effect of whole coffee fruit concentrate powder (NeuroFactor), green coffee caffeine powder, grape seed extract powder and green coffee bean extract powder on blood levels of BDNF. Randomly assorted groups of fasted subjects consumed a single, 100 mg serving of each material. Plasma samples were collected at time zero (T0) and at 30 minute intervals afterwards, up to 120 minutes. Two control groups were included: subjects treated with silica dioxide (as placebo) or with no treatment.

**Collected data revealed that treatment with NeuroFactor increased plasma levels of BDNF by 143%** (n=10) compared to baseline. These results indicate that NeuroFactor could be used for modulation of BDNF-dependent health conditions in Humans.

### NeuroFactor: Exclusively from FutureCeuticals

NeuroFactor is available exclusively from FutureCeuticals. FutureCeuticals is cGMP and HACCP-certified, a voting member of the Council for Responsible Nutrition, a voting member of the International Probiotics Association, and a member of the American Botanical Council.

### Modulatory Effect on Plasma Levels of BDNF



## NeuroFactor™ Increases Plasma Levels of BDNF in Humans

- <sup>i</sup> Gooney M, Shaw K, Kelly A, O'Mara SM, Lynch MA. Long-term potentiation and spatial learning are associated with increased phosphorylation of TrkB and extracellular signal-regulated kinase (ERK) in the dentate gyrus: evidence for a role for brain-derived neurotrophic factor. *Behav Neurosci* 2002;116(3):455-63.
- <sup>ii</sup> Hennigan A, Callaghan CK, Kealy J, Rouine J, Kelly AM. Deficits in LTP and recognition memory in the genetically hypertensive rat are associated with decreased expression of neurotrophic factors and their receptors in the dentate gyrus. *Behav Brain Res* 2009;197(2):371-7.
- <sup>iii</sup> Hennigan A, O'Callaghan RM, Kelly AM. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. *Biochem Soc Trans* 2007;35(Pt 2):424-7.
- <sup>iv</sup> Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. *Learn Mem* 2002;9(5):224-37.
- <sup>v</sup> Knaepen K, Goekint M, Heyman EM, Meeusen R. Neuroplasticity – exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects. *Sports Med* 2010;40(9):765-801.
- <sup>vi</sup> Wisse BE, Schwartz MW. The Skinny on neurotrophins. *Nat Neurosci* 2003;6:736-742.
- <sup>vii</sup> Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, Yanovski JA, El Gharbawy A, Han JC, Tung YC, Hodges JR, Raymond FL, O'Rahilly S, Farooqi IS. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. *Diabetes* 2006;55:3366-3371.
- <sup>viii</sup> Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadóttir A, Styrkarsdóttir U, Gretarsdóttir S, Thorlacius S, Jonsdóttir I, Jonsdóttir T, Olafsdóttir EJ, Olafsdóttir GH, Jonsson T, Jonsson F, Borch-Johnsen K, Hansen T, Andersen G, Jorgensen T, Lauritzen T, Aben KK, Verbeek AL, Roeleveld N, Kampman E, Yanek LR, Becker LC, Tryggvadóttir L, Rafnar T, Becker DM, Gulcher J, Kiemeneý LA, Pedersen O, Kong A, Thorsteinsdóttir U, Stefansson K. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet* 2009;41:18-24.
- <sup>ix</sup> Krabbe, K. S., Nielsen, A. R., Krogh-Madsen, R., Plomgaard, P., Rasmussen, P., Erikstrup, C., et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. *Diabetologia* 2007;50:431-438.
- <sup>x</sup> Chaldakov, G. N., Fiore, M., Stankulov, I. S., Hristova, M., Antonelli, A., Manni, L., et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. *Archives of Physiology and Biochemistry* 2001;109:357-360.
- <sup>xi</sup> Manni, L., Nikolova, V., Vyagova, D., Chaldakov, G. N., Aloe, L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. *International Journal of Cardiology* 2005;102:169-171.
- <sup>xii</sup> Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J. M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. *Psychiatry Research* 2002;109:143-148.
- <sup>xiii</sup> Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Wittorf, A., Richartz, E., et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. *Journal of Neural Transmission* 2006;113:1217-1224.
- <sup>xiv</sup> Peng, S., Wu, J., Mufson, E. J., Fahnstock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. *Journal of Neurochemistry* 2005;93:1412-1421.
- <sup>xv</sup> Holsinger, R. M., Schnarr, J., Henry, P., Castelo, V. T., Fahnstock, M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: Decreased levels in Alzheimer's disease. *Molecular Brain Research* 2000;76:347-354.